A Phase III Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: SKB264|DRUG: Eribulin|DRUG: Capecitabine|DRUG: Gemcitabine|DRUG: Vinorelbine
Sponsor: Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.